Physician profile
David P Harris
NPI 1639147036
$3,820.52
in general payments reported to CMS, 2019-2025
28 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $325 · 2021: $547 · 2022: $455 · 2023: $882 · 2024: $887 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $613.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $589.65 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $445.99 | 2022-2024 | |
| Lilly USA, LLC | $441.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $324.42 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $249.01 | 2023-2025 | |
| Exact Sciences Corporation | $230.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $225.67 | 2019-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.14 | 2020-2025 | |
| Abbvie INC. | $68.57 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $63.37 | 2021-2024 | Airsupra, Breztri |
| Boston Scientific Corporation | $57.80 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $42.20 | 2020-2024 | Injectafer |
| Abbott Laboratories | $38.52 | 2021-2025 | Freestyle Libre 3 |
| Philips North America LLC | $36.51 | 2024 | (Ck7) Extended Holter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $35.64 | 2022-2023 | Wellbutrin, Aplenzin |
| Allergan, INC. | $28.45 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $25.85 | 2021 | |
| Abiomed | $24.88 | 2023 | Impella |
| Astellas Pharma US INC | $24.05 | 2019-2020 | |
| Shield Therapeutics INC | $23.67 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.06 | 2023 | Vpriv |
| Biohaven Pharmaceutical Holding Company LTD. | $22.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.66 | 2023 | Quviviq |
| Amarin Pharma, INC. | $17.53 | 2021 | |
| Nevro Corp. | $16.07 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $13.57 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.